At a glance
ClinicalIndex Comparison RecordN/ACompleted· 116 enrolled
Drug / intervention
Tigecycline (Tygacil)drug
Likely dose
Tigecycline (Tygacil) 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-Drug Resistance.)
In Brief
An observational study evaluating Tigecycline (Tygacil) for Intra-Abdominal Infections and Skin Disease, Infectious. Completed, enrolled 116 participants.
Detailed Summary
Secondary Data Collection Study; safety and effectiveness of Tigecycline .under Japanese medical practice
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartApr 2013
Primary CompletionJun 2017
TodayJul 2026
First PostedFeb 12, 2013
Enrollment StartApr 15, 2013
Primary CompletionJun 16, 2017
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.4 years ago
Interventions
Tigecycline (Tygacil)drug
Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.